1 patent currently held
32 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2034. from the record
Of the 32 now held by other companies, 32 name Roche Molecular Systems Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2034
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Jan 2031 · High confidence
The most cited patent in this portfolio, cited by 303 later US patents, top 1% of utility patents granted in 2019 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
now held by Roche Molecular Systems, Inc.
Also notable
Ends no later than Sep 2032 · Medium confidence
Cited by 210 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Roche Molecular Systems, Inc.
Also notable
Ends Sep 2036 · High confidence
Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
now held by Roche Molecular Systems, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Processes for Calculating Phased Fetal Genomic Sequences | 1 in force | to May 2034 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,744,106 | Processes for Calculating Phased Fetal Genomic Sequences In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 32 patents in force now held by others · 3 applications pending · 26 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed